A Phase I trial of AR1003 for Sepsis.
Phase of Trial: Phase I
Latest Information Update: 20 Oct 2016
At a glance
- Drugs AR 1003 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- 20 Oct 2016 New trial record
- 01 Jun 2016 According to an AriBio media release, this trial will be conducted in 2017 after granting FDA IND license.